Anti-viral activity of enisamium iodide against viruses of influenza and ARVI’s on different cell lines
- 作者: Zarubaev V.1, Slita A.1, Sinegubova E.1, Muryleva A.1, Lavrentieva I.1
-
隶属关系:
- Saint Petersburg Pasteur Institute
- 期: 卷 92, 编号 11 (2020)
- 页面: 45-50
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/56929
- DOI: https://doi.org/10.26442/00403660.2020.11.000872
- ID: 56929
如何引用文章
全文:
详细
Influenza and ARVI represent the most numerous and dangerous group of causative agents of respiratory infections human.
Aim. Characterization of the antiviral properties of enisamium iodide against human respiratory viruses in in vitro experiments.
Materials and methods. In the course of experiments, the cytotoxic properties of enisamium iodide were studied against the cell lines Vero, MA-104, A549, L-41 and HEp-2. The antiviral activity of enisamium iodide was studied using virus yield reduction assay against influenza viruses, parainfluenza virus, respiratory syncytial virus, Coxsackie B3 and Coxsackie B4 viruses, as well as adenoviruses types 5 and 6.
Results. The most sensitive to the action of enisamium iodide was the human parainfluenza virus, whose activity decreased by 2.3 orders of magnitude under the action of the drug in A549 cells. Of the cell cultures used, enisamium iodide exhibited the maximum antiviral effect in human lung carcinoma cells A549, where, in its presence, the level of reproduction of adenoviruses of types 5 and 6, Coxsackie viruses B3 and B4, and human parainfluenza virus decreased by an order of magnitude or more. The antiviral activity of enisamium iodide was least manifested in Vero cells.
Conclusion. According to the results of in vitro experiments, enisamium iodide can be considered as an antiviral drug with a wide spectrum of activity against human respiratory viruses.
作者简介
V. Zarubaev
Saint Petersburg Pasteur Institute
编辑信件的主要联系方式.
Email: zarubaev@gmail.com
ORCID iD: 0000-0002-5224-3771
д.б.н., ст. науч. сотр. лаб. экспериментальной вирусологии
俄罗斯联邦, Saint PetersburgA. Slita
Saint Petersburg Pasteur Institute
Email: zarubaev@gmail.com
ORCID iD: 0000-0001-8229-0715
д.б.н., ст. науч. сотр. лаб. экспериментальной вирусологии
俄罗斯联邦, Saint PetersburgE. Sinegubova
Saint Petersburg Pasteur Institute
Email: zarubaev@gmail.com
ORCID iD: 0000-0001-9490-2280
мл. науч. сотр. лаб. экспериментальной вирусологии
俄罗斯联邦, Saint PetersburgA. Muryleva
Saint Petersburg Pasteur Institute
Email: zarubaev@gmail.com
мл. науч. сотр. лаб. экспериментальной вирусологии
俄罗斯联邦, Saint PetersburgI. Lavrentieva
Saint Petersburg Pasteur Institute
Email: zarubaev@gmail.com
зав. лаб. экспериментальной вирусологии
俄罗斯联邦, Saint Petersburg参考
- Ruuskanen O, Meurman O, Sarkkinen H. Adenoviral diseases in children: a study of 105 cases. Pediatrics. 1985;76:79-83.
- Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98:174-85. doi: 10.1016/j.antiviral.2013.03.014
- Steel J, Lowen AC. Influenza A virus reassortment. Curr Top Microbiol Immunol. 2014;385:377-401. doi: 10.1007/82_2014_395
- Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242-64.
- Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264-75.
- Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol. Immunol. 1984;110:191-220.
- Erdman DD, Xu W, Gerber SI, et al. Molecular epidemiology of adenovirus type 7 in the United States, 1966–2000. Emerg Infect Dis. 2002;8:269-77.
- Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1997;27:1197-200.
- Azbug MJ, Levin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics. 1991;87:890-6.
- Rosario RF, Kimbrough RC, Van Buren DH, Laski ME. Fatal adenovirus serotype-5 in a deceased-donor renal transplant recipient. Transpl Infect Dis. 2006;8(1):54-7.
- Abarca VK, Le Corre PN, Perret PC, et al. Disseminated and fatal adenovirus infection in an immunocompromised child. Rev Chilena Infectol. 2008;25(2):127-32.
- Boltz D, Peng X, Muzzio M, et al. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. doi: 10.1177/2040206618811416
- Hume A, Mühlberger E. Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner J Infect Dis. 2018;218(Suppl_5):S403-S408. doi: 10.1093/infdis/jiy473
- Zurney J, Howard KE, Sherry B. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol. 2007;81(24):13668-80. doi: 10.1128/JVI.01172-07
- Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol. 2005;79(20):12944-51. doi: 10.1128/JVI.79.20.12944-12951.2005
- Goutagny N, Jiang Z, Tian J, et al. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J Immunol. 2010;184(3):1168-79. doi: 10.4049/jimmunol.0902750
- Mesa B. The Effect of Cell Type on the Efficacy of CMV Antiviral Drugs. Virginia Commonwealth University, 2008.
- Chung D. The Establishment of an Antiviral State by Pyrimidine Synthesis Inhibitor is Cell Type-Specific. J Antimicrob Agents. 2015;1(1):101.
- Cocking D, Cinatl J, Boltz DA, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol. 2018;62(2):191-5. doi: 10.4149/av_2018_211
- Haltner-Ukomadu E, Gureyeva S, Burmaka O, et al. In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide. Sci Pharm. 2018;86(1):3. doi: 10.3390/scipharm86010003
- Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol. 1986 Jun;6(6):2279-83. doi: 10.1128/mcb.6.6.2279
- Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43(1):247-52. doi: 10.1099/0022-1317-43-1-247